« Previous
Next »
Fertility and Sterility
Volume 91, Issue 3
, Pages
659-663
, March 2009
Return to fertility following discontinuation of oral contraceptives
To access this article, please choose from the options below
Supported by Wyeth Pharmaceuticals, Collegeville, PA. The authors were not compensated and retained full editorial control over the content of the manuscript.
K.B. has served as a clinical trial investigator for Wyeth-Ayerst, Organon, Johnson & Johnson, Duramed, Xanodyne, Boehringer Ingelheim, Third Wave, Pfizer, and MGI Pharma; he has served as a consultant for Novo Nordisk and on the Speaker Bureau for Organon. C.A.S. has nothing to disclose.
PII: S0015-0282(09)00049-1
doi: 10.1016/j.fertnstert.2009.01.003
© 2009 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
Fertility and Sterility
Volume 91, Issue 3
, Pages
659-663
, March 2009

